STEP-1

The pivotal Phase 3 trials and post-approval cardiovascular, kidney, and sleep-apnea outcome studies.

Definition

Pivotal Phase 3 trial of semaglutide 2.4 mg weekly vs placebo in 1,961 adults with overweight/obesity (Wilding et al, NEJM 2021, PMID 33567185). Mean weight loss 14.9% at 68 weeks.

STEP-1 side-effect data investigation →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in Major trials

SURMOUNT-1
SELECT
FLOW
SURMOUNT-OSA
STEP-TEENS

Looking for more depth?

STEP-1 side-effect data investigation
Browse the full GLP-1 glossary (51 terms across 8 categories)
Research articles — primary-source deep dives
Tools and calculators
Compare GLP-1 telehealth providers